Home›Trial›NCT06966401
🔬NCT06966401Phase 3RECRUITING

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Study Summary

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Conditions
Major Depressive Disorder
Interventions / Drugs
NBI-1065845
View on ClinicalTrials.gov ↗
Sponsor
NBIX
Neurocrine Biosciences
Neuroscience
D50/100
Study Details
Enrollment600 participants
Primary Completion—
Lead SponsorNeurocrine Biosciences
Data Retrieved2026-04-11 04:22:17.614586+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.